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Poster Session I 81iron overload pre-HSCT who required aggressive iron manage-
ment post-HSCT. Liver iron concentration (LIC), a surrogate of
total body iron burden, was assessed by liver biopsy and/ormagnetic
reasonance imaging (T2* or R2 MRI). Abnormal LIC was defined
as .1.5 mg iron/g dry liver tissue. Results: Patient characteristics
are presented in Table 1. 7 out of the 11 patients identified were
not previously known to have iron overload. The majority of these
patients presented with elevations in liver transaminases as the pri-
mary sign of excess iron. Liver biopsy and/or MRI were used to di-
agnose iron overload, and in all cases MRI was the method used to
assess the change in iron burden while patients were receiving ther-
apy. Most patients were managed with phlebotomy (range: 4–10 cc/
kg of blood removed every 2–4 weeks). Phlebotomy was effective in
reducing iron burden as evidenced by normalization of transami-
nases and decrease in LIC and ferritin. One patient, managed
with an oral iron chelator, did not have a reduction of overall iron
burden. Conclusions: . Iron overload should be considered in
HSCTpatients presenting with abnormal transaminases and/or hy-
perferritinemia after transplant. MRI is a useful diagnostic tool and
may obviate the need for invasive liver biopsy. Phlebotomy appears
to be effective in reducing iron burden, however the safety and effi-
cacy of chelators is not yet established. There is a need for prospec-
tive studies to define the prevalence of iron overload, establish
guidelines for screening, and develop safe and effective therapies.
As a result, we have initiated a prospective study using R2 MRI to
determine the incidence and morbidity associated with iron over-
load in this patient population.
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Leukemia, MURD 5 Matched Unrelated Donor, MRD 5
Matched Related Donor, ALT 5 Alanine Aminotransferase.
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Genetic mutations affecting regulatory proteins of NF-kB result
in heritable diseases of development and immunity. Hypomorphic,
X-linked mutations in the IKBKG gene (NEMO protein), and hy-
permorphic, autosomal dominant mutations in the IKBA gene
(IkBa protein), are associated with a phenotype of ectodermal dys-
plasia with immune deficiency (ED-ID). ED-ID predisposes pa-
tients to bacterial and mycobacterial infections, and is typically
fatal. Allogeneic HSCT may correct the immune deficiency associ-
ated with NEMO or IkBamutations, but there are few reports. We
report 3 patients with ED-ID who underwent HSCT. All patients
experienced engraftment difficulties. Patient 1 presented with fe-
vers, diarrhea, diffuse erythema and desquamation. Hypogamma-
globulinemia with normal B- and T- cell numbers and subsets
were noted, and genetic analysis revealed a hypomorphic NEMO
mutation. He received matched sibling donor peripheral blood
stem cells (PBSC) at 6 months following reduced-intensity condi-
tioning with fludarabine, busulfan and ALG. Neutrophil engraft-
ment was achieved at day 117, and maximal donor T-cell
chimerism of 53% at day 177, which then declined. A second
PBSCT from the same donor was undertaken after conditioning
with alemtuzumab, fludarabine and melphalan, with stable donor
chimerism through day1310. Patient 2 developed diarrhea, failure
to thrive and recurrent infections including MAI. Inadequate anti-
body responses, but normal B- and T- cell numbers and subsets
were noted. Genetic analysis demonstrated a hypomorphic
NEMO mutation. A MUD BMT was performed at 3 years of age
following myeloablative conditioning with busulfan, cyclophospha-
mide and ALG. Poor engraftment was noted, with persistent neu-
tropenia despite chimerism of 95% donor at day 138. The
patient was re-conditioned with fludarabine, and a CD34-selected
PBSC boost from the same donor. Although complete chimerism
was achieved, the patient remained pancytopenic and died at day
1314 of gram-negative infection. Patient 3 presented with recur-
rent bacterial infections, p.carinii, and chronic diarrhea. Genetic
analysis confirmed an IkBa mutation. The patient underwent
a MUD cord blood transplant following myeloablative condition-
ing with busulfan and cyclophosphamide, but expired from sepsis
prior to engraftment. These cases suggest that patients with im-
mune deficiencies caused by NEMO or IkBa mutations may have
intrinsic barriers to successful engraftment, which require further
investigation.
218
LOWER LEUKEMIA RELAPSE IN PATIENTS WITH PULMONARY CYTO-
LYTIC THROMBI AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANT
Verneris, M.R.1, Gulbahce, E.2, Burke, M.1, Cao, Q.1,
MacMillan, M.L.1, Tolar, J.1, Orchard, P.1, Blazar, B.R.1, Baker, S.1,
Wagner, J.E.1. 1University of Minnesota, Minneapolis, MN; 2Univer-
sity of Minnesota, Minneapolis, MN.
Pulmonary cytolytic thrombi (PCT) is an uncommon post-trans-
plant complication, which is more commonly reported in children
than adults. PCT typically presents with low grade fever, cough,
shortness of breath and/or hypoxia. Lung CT findings range from
small, peripheral nodules to large diffuse infiltrates. The diagnosis
is established by lung biopsy, which reveals areas of the pulmonary
vasculature which are occluded with cellular debris. Bronchoscopy
and lung biopsy are negative for infectious organisms by both im-
muno-stains and culture.While the pathogenesis of PCT is not cur-
rently known, it has been previously shown that patients with PCT
frequently have concurrent aGVHD and that PCT responds to sys-
temic corticosteroid treatment. Considering that such treatment
may impair graft vs. leukemia (GVL) reactions, we investigated
the outcome of patients who developed PCT after transplantation
for hematological malignancy. From 1993–2006, we identified 14
pediatric patients with biopsy proven PCT and a hematological ma-
lignancy (9 ALL, 3 AML and 2 CML). PCTwas diagnosed at an av-
erage of 901/-38 days (range 38–342) after transplant. We
compared outcomes to a cohort of pediatric leukemia patients
that not develop PCT, but were transplanted during the same
time interval (n 5 323). There were no significant differences
